Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species
Study suggests a mechanism for EZH2 (show EZH2 ELISA Kits)-H3K27me3 epigenetic repression of DLC1 (show DYNLL1 ELISA Kits) and multilayered regulation of DLC1 (show DYNLL1 ELISA Kits)/Rho/ROCK signaling by EZH2 (show EZH2 ELISA Kits), and advocated the significant pro-metastatic role of EZH2 (show EZH2 ELISA Kits) via repressing tumor and metastasis suppressors.
The results identify DLC1 (show DYNLL1 ELISA Kits) as an activator of white and brown adipocyte differentiation, and provide a molecular link between PPARgamma (show PPARG ELISA Kits) and Rho pathways.
DLC-1 (show DYNLL1 ELISA Kits) has a positive regulatory role in endothelial cell angiogenesis.
Subsequent studies have demonstrated that DLC-1 (show DYNLL1 ELISA Kits) is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 (show DYNLL1 ELISA Kits) as a potential tumor suppressor. [review]
Tumor suppressor genes deleted in liver cancer 1 (DLC1), F-box/WD-repeat-containing protein 7 (FBXW7 (show FBXW7 ELISA Kits)), and cadherin-6 (CDH6 (show CDH6 ELISA Kits)) were identified as presumed targets in Cholangiocarcinoma (CC).Inverse correlation between promoter methylation and expression suggested miR (show MLXIP ELISA Kits)-129-2 and members of the miR (show MLXIP ELISA Kits)-200 family (miR (show MLXIP ELISA Kits)-200a, miR (show MLXIP ELISA Kits)-200b, and miR (show MLXIP ELISA Kits)-429) as novel tumor suppressors and oncomiRs, respectively, in CC
the expression levels of DLEC1 and ITGA9 were prominently decreased in lung tumor samples
it was demonstrated that the rs621554 polymorphism was correlated with DLC1 (show DYNLL1 ELISA Kits) expression at the mRNA level. These results suggested that the rs621554 polymorphism is associated with breast cancer susceptibility and prognosis, and may serve as a biomarker for breast cancer development and progression.
curcumin down-regulates the expression of Sp1 (show PSG1 ELISA Kits) to inhibit the expression of DNA methyltransferase 1 (show DNMT1 ELISA Kits), thus subsequently reducing hypermethylation of DLC1 (show DYNLL1 ELISA Kits) promoter to induce DLC1 (show DYNLL1 ELISA Kits) expression.
DLC-1 (show DYNLL1 ELISA Kits) acts as a tumor suppressor gene in HCC (show FAM126A ELISA Kits) by regulating the expression of RhoA (show RHOA ELISA Kits)/ROCK2 (show ROCK2 ELISA Kits)/ moesin (show MSN ELISA Kits).
Low DLC-1 (show DYNLL1 ELISA Kits) expression is associated with cancer.
DLC-1 has a positive regulatory role in endothelial cell angiogenesis.
studies demonstrate that TNS1 (show TNS1 ELISA Kits) binds to DLC1 and fine-tunes its RhoGAP (show ARHGAP1 ELISA Kits) activity toward RhoA (show RHOA ELISA Kits) and that the TNS1 (show TNS1 ELISA Kits)-DLC1-RhoA (show RHOA ELISA Kits) signaling axis is critical in regulating cellular functions that lead to angiogenesis
Loss of expression of only Dlc1 isoform 2 may be sufficient for the development of thymic tumors and metastasis.
Several genes and biochemical activities collaborate with the inactivation of DLC1 to give rise to cell transformation in MEFs, and the identified genes are relevant to human tumors with low DLC1 expression.
The Dlc1 deficient cells showed altered cytoskeleton structure, increased RhoA (show RHOA ELISA Kits) activity and cellular migration.
DLC-1-/- embryos had defects in the neural tube, brain, heart, and placenta
Our data validate DLC1 as a potent tumor suppressor gene and suggest that its loss creates a dependence on the RhoA (show RHOA ELISA Kits) pathway that may be targeted therapeutically.
This gene contains 37 exons, spans approximately 59-kb, and is located in the 3p22-p21.3 chromosomal segment that is commonly deleted in various carcinomas. Several alternatively spliced transcripts have been observed that contain disrupted coding regions and likely encode nonfunctional proteins. Aberrant transcription of this gene may be involved in carcinogenesis of the lung, esophagus, and kidney.
deleted in liver cancer 1
, rho GTPase-activating protein 7-like
, Rho-GTPase-activating protein 7
, START domain-containing protein 12
, StAR-related lipid transfer (START) domain containing 12
, deleted in liver cancer 1 protein
, deleted in liver cancer 1 variant 2
, rho GTPase-activating protein 7
, rho-type GTPase-activating protein 7
, stAR-related lipid transfer protein 12
, deleted in liver cancer 1 protein homolog
, rho GTPase activating protein 7
, Deleted in liver cancer 1 protein homolog
, Rho-type GTPase-activating protein 7
, deleted in lung and esophageal cancer 1 transcript varient 2
, deleted in lung and esophageal cancer protein 1